Press Releases

February 11, 2021

ProterixBio announces commercial availability of a quantitative COVID-19 serology test validated for dried blood spots from a finger stick

Billerica, MA, February 11, 2020: ProterixBio, Inc. announced today commercial availability of a quantitative COVID-19 serology assay that has been validated for dried blood spots (DBS) from a finger stick. This is an update to the previously released SARS-CoV-2 (RBD) IgG Antibody test and is being offered as a testing service through ProterixBio’s high-complexity CLIA… Read more »

September 28, 2020

ProterixBio Announces Commercial Availability of a Semi-Quantitative COVID-19 Antibody Test

Billerica, MA, September 29, 2020: ProterixBio, Inc. announced today commercial availability of the SARS-CoV-2 (RBD) IgG Antibody test, a semi-quantitative COVID-19 serology assay. It is being offered as a testing service through ProterixBio’s high-complexity clinical testing laboratory. Validation results demonstrated a Positive Percent Agreement (PPA) of 100% for samples acquired >15 days after symptoms onset… Read more »

July 1, 2020

ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital

Billerica, MA, July 1, 2020: ProterixBio, Inc. today announced completing a licensing agreement with the Massachusetts General Hospital for a COVID-19 serology assay. The assay was developed and validated by researchers at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University which is a joint venture of Harvard University, Massachusetts… Read more »